A detailed history of Geneos Wealth Management Inc. transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Geneos Wealth Management Inc. holds 89,725 shares of AVXL stock, worth $509,638. This represents 0.02% of its overall portfolio holdings.

Number of Shares
89,725
Previous 74,400 20.6%
Holding current value
$509,638
Previous $378,000 -0.0%
% of portfolio
0.02%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 23, 2024

BUY
$3.39 - $5.02 $51,951 - $76,931
15,325 Added 20.6%
89,725 $378,000
Q1 2024

May 03, 2024

BUY
$4.55 - $6.75 $30,940 - $45,900
6,800 Added 10.06%
74,400 $378,000
Q4 2023

Jan 26, 2024

BUY
$5.04 - $9.95 $128,520 - $253,724
25,500 Added 60.57%
67,600 $629,000
Q1 2023

Apr 25, 2023

BUY
$8.32 - $11.75 $16,640 - $23,500
2,000 Added 4.99%
42,100 $360,000
Q4 2022

Jan 30, 2023

BUY
$7.65 - $14.43 $50,490 - $95,238
6,600 Added 19.7%
40,100 $371,000
Q3 2022

Nov 14, 2022

SELL
$8.9 - $12.86 $47,170 - $68,158
-5,300 Reduced 13.66%
33,500 $345,000
Q2 2022

Jul 22, 2022

BUY
$7.31 - $12.84 $52,266 - $91,806
7,150 Added 22.59%
38,800 $388,000
Q1 2022

May 16, 2022

BUY
$9.74 - $17.69 $89,608 - $162,748
9,200 Added 40.98%
31,650 $389,000
Q3 2021

Nov 09, 2021

BUY
$16.82 - $25.75 $15,979 - $24,462
950 Added 4.42%
22,450 $402,000
Q2 2021

Jul 08, 2021

SELL
$10.16 - $28.86 $40,640 - $115,440
-4,000 Reduced 15.69%
21,500 $528,000
Q1 2021

Jun 17, 2021

BUY
$5.17 - $16.13 $5,170 - $16,129
1,000 Added 4.08%
25,500 $308,000
Q4 2020

May 19, 2021

BUY
$4.01 - $7.58 $2,005 - $3,790
500 Added 2.08%
24,500 $366,000
Q3 2020

Sep 07, 2021

BUY
$3.8 - $5.0 $38,000 - $50,000
10,000 Added 71.43%
24,000 $92,000
Q3 2018

Sep 07, 2021

BUY
$2.23 - $3.82 $31,220 - $53,480
14,000 New
14,000 $38,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $443M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Geneos Wealth Management Inc. Portfolio

Follow Geneos Wealth Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geneos Wealth Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Geneos Wealth Management Inc. with notifications on news.